	XIAF	LEX® (co	llagen	ase clost	ridiun	n histo	lyticu	m)	_		
											IIER →
HEALTH INSUR APPROVED BY NATIONAL UI	ANCE CLAIM  JIFORM CLAIM COMMIT			Med	icare P	art B Cla	aims				CARRIER
PICA  1. MEDICARE MEDIC	AID TRICARE	CHAMPVA	GROUI	P EECA	OTHER	1a. INSURED'S	ID NUMBER		(For Pro	PICA pgram in Item 1)	J¥
(Medicare#) (Medica	)#) HEALT (ID#)	FECA H PLAN FECA BLK LUN (ID#)	123-45-6789A 4. INSURED'S NAME (Last Name, First Name, Middle Initial)					_ ^			
PATIENT'S NAME (Last Na <b>Doe, John Q.</b>		nitial)	3. PATIENT'S MM   DI 10   19	1935 MX	F	4. INSURED'S I	NAME (Last N	ame, First Na	me, Middle Init	ia <b>l</b> )	
5. PATIENT'S ADDRESS (No 1212 Main St.	, Street)			ELATIONSHIP TO INSI	JRED Other	7. INSURED'S /	ADDRESS (No	., Street)			
OITY Any City		STATE XX	8. RESERVED	FOR NUCC USE		CITY				STATE	
ZIP CODE	TELEPHONE (Includ	de Area Code)				ZIP CODE		TELEPH	IONE (Include	Area Code)	-MAT
XXXXX 9. OTHER INS	(123) 555-1	1212						(_	)		_R   N
a. OTHER INS		SA	MPL	E 150	O FC	)RM					_ 교
AARP		SINGI	F C	ORD TI	SΕV.	TMF	NT			F 🗌	INSU
Daned o								ا الحالية	o rooulu-		PATIENT AND INSURED INFORMATION
	n prior policy, this on of claim forms			•			, ,	-			IENT
. INSURANC replace	or modify your MA	AC's policy, an	d use of th	s form does not	guarante	e payment d	r take the	place of			– ₽
	onal coding advicates that most ac	• .							•	d 9d. uthorize supplier for	+
to process	o change. Please	•				•				10 supplier for	
	or treatment recor	mmendation.								PATION	<b>=</b> <sup>↑</sup>
4. DATE OF DEFENDING R	QUAL.	QUA	<del>                                      </del>	MM   DD	YY	FROM  18. HOSPITALIZ  MM	DD	YY C DEL ATED	TO CURRENT	PATION YY	$\exists \widehat{\ }$
7. NAME OF REFERRING P	HOVIDER OR OTHER SC		NPI			FROM	DD	YY	TO TO	DD YY	
9. ADDITIONAL CLAIM INFO	RMATION (Designated b	y NUCC)				20. OUTSIDE L	AB?		\$ CHARGES		
1. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E)  ICD Ind.						22. RESUBMISSION ORIGINAL REF. NO.					
A. <b>W172.U</b> E. <b>L</b>	В. L F. L			- D.		23. PRIOR AUT	HORIZATION	NUMBER			$\exists 1$
I 24. A DATE(S) OF SER'				_ L. L CES, OR SUPPLIES	E.	F.	G.	H.	l.	J.	- -  -
From MM DD YY MM	To PLACE OF DD YY SERVICE	EMG CPT/HCPC	in Unusual Circu CS	MODIFIER	DIAGNOSIS POINTER	\$ CHARGE	G. DAY: OR UNIT	H. EPSDT Family S Plan QU		RENDERING ROVIDER ID. #	ATION
10 03 21 10	03 21 11	J0775			Α	XXX	XX 58	- N	T	hese amounts	are
10 03 21 10	03 21 11	J0775	JW		Α	XXX	XX   32	N		rovided as an e	
10 03 21 10	03 21 11	20527	1		Α	XXX	XX 1	-	4	ose and wasta	
			11 84/	P.C. 1 . 1 . P.				1		ccordance with IAFLEX® Presci	
10 05 21 10	05 21 11	26341		modifier to indicate the drug is waste		XXX	XX 1	N		iarlex <sup>®</sup> Presci	ווטוו
<u> </u>	i l			gle-use vial.				N	PI		5
5. FEDERAL TAX I.D. NUME	ER SSN EIN	26. PATIENT'S A	CCOUNT NO	27. ACCEPT AS	SIGNMENT?	28. TOTAL CHA	RGE	29. AMOUN		D. Rsvd for NUCC Us	. HA
123456789				X YES	NO	\$ X	xxx xxx	\$		XXXX XX	
B1. SIGNATURE OF PHYSICI INCLUDING DEGREES O (I certify that the statemen apply to this bill and are m	R CREDENTIALS s on the reverse	32. SERVICE FA	CILITY LOCATION	ON INFORMATION		33. BILLING PR	OVIDER INFO	)&PH# (	)		
NONED	0.475	a.	b.			a. N	PI	b.			$- \downarrow \downarrow$
SIGNED UCC Instruction Manu	DATE al available at: www	PLEASE PRINT OR TYPE			APPROVED OMB-0938-1197 FORM 1500 (02-12)						

## **INDICATION**

XIAFLEX® is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.

## IMPORTANT SAFETY INFORMATION FOR XIAFLEX

- XIAFLEX is contraindicated in patients with a history of hypersensitivity to XIAFLEX or to collagenase used in any other therapeutic
  application or application method
- In the controlled and uncontrolled portions of clinical trials in Dupuytren's contracture, flexor tendon ruptures occurred after XIAFLEX injection. Injection of XIAFLEX into collagen-containing structures such as tendons or ligaments of the hand may result in damage to those structures and possible permanent injury such as tendon rupture or ligament damage. Therefore, XIAFLEX should be injected only into the collagen cord with a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint contracture, and care should be taken to avoid injecting into tendons, nerves, blood vessels, or other collagen-containing structures of the hand. When injecting a cord affecting a PIP joint of the fifth finger, the needle insertion should not be more than 2 to 3 mm in depth and avoid injecting more than 4 mm distal to the palmar digital crease
- Other XIAFLEX-associated serious local adverse reactions in the controlled and uncontrolled portions of the clinical studies included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear). In a historically controlled post-marketing trial, the incidence of skin laceration (22%) was higher for subjects treated with two concurrent injections of XIAFLEX compared with subjects treated with up to three single injections in the placebo-controlled premarketing trials (9%). Post-marketing cases of skin laceration requiring skin graft after finger extension procedures and local skin and soft-tissue necrosis, some requiring skin grafting, or other surgical interventions including finger amputation have been reported. Signs or symptoms that may reflect serious injury to the injected finger/hand should be promptly evaluated because surgical intervention may be required
- Cases of syncope and presyncope have been reported in the post-marketing period in patients treated with XIAFLEX. In most cases in
  patients with Dupuytren's contracture, the injection procedure, finger extension procedure, or pain following the procedures were reported
  as potential triggers for the events, suggesting a vasovagal mechanism. Most, but not all, cases occurred in the immediate treatment
  period (injection or finger extension procedure) or within 1 to 2 days following the injection or finger extension procedure. If presyncopal
  symptoms occur, patients should remain recumbent until symptoms resolve. Syncope may be associated with bodily injuries, including
  concussion, head abrasion, and other accidental injuries
- In the controlled portions of the clinical trials in Dupuytren's contracture, a greater proportion of XIAFLEX-treated patients (15%) compared
  to placebo-treated patients (1%) had mild allergic reactions (pruritus) after up to 3 injections. The incidence of XIAFLEX-associated
  pruritus increased after more XIAFLEX injections in patients with Dupuytren's contracture
- Because XIAFLEX contains foreign proteins, severe allergic reactions to XIAFLEX can occur. Anaphylaxis was reported in a post-marketing
  clinical trial in one patient who had previous exposure to XIAFLEX for the treatment of Dupuytren's contracture. Healthcare providers
  should be prepared to address severe allergic reactions following XIAFLEX injections
- In the XIAFLEX trials in Dupuytren's contracture, 70% and 38% of XIAFLEX-treated patients developed an ecchymosis/contusion or an injection site hemorrhage, respectively. Patients with abnormal coagulation (except for patients taking low-dose aspirin, eg, up to 150 mg per day) were excluded from participating in these studies. Therefore, the efficacy and safety of XIAFLEX in patients receiving anticoagulant medications (other than low-dose aspirin, eg, up to 150 mg per day) within 7 days prior to XIAFLEX administration is not known. In addition, it is recommended to avoid use of XIAFLEX in patients with coagulation disorders, including patients receiving concomitant anticoagulants (except for low-dose aspirin)
- In the XIAFLEX clinical trials for Dupuytren's contracture, the most common adverse reactions reported in ≥25% of patients treated with XIAFLEX and at an incidence greater than placebo were edema peripheral (eg, swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the injected extremity
- <u>Post-marketing experience</u> Syncope and presyncope have been reported in patients treated with XIAFLEX. Most, but not all, cases
  occurred in the immediate treatment period or within 1 to 2 days following injection. Bodily injuries associated with the syncopal events
  have been reported

Click for full Prescribing Information, including Medication Guide.



